1. Malaysia Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Optimax Holdings Bhd.

Optimax Holdings Bhd.

MMYX:OPTIMAX
0.50
MYR
0.00
(0.00%)
22.30P/E
Dec 02Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.06
0.07
0.09
0.12
0.13
0.16
0.2
0.21
0.24
0.25
0.26
Basic EPS, GAAP
0.01
0.01
0.01
0.01
0.01
0.02
0.03
0.02
0.02
0.03
0.02
Free Cash Flow per Basic Share
-0.02
0.01
0.01
0.02
0.02
0.02
0.03
0.02
- -
0.05
0.05
Dividend per Share
- -
- -
- -
0.01
- -
0.01
0.02
0.02
0.01
0.01
0.01
Book Value per Share
0.02
0.03
0.04
0.04
0.09
0.1
0.11
0.12
0.12
0.14
0.14
Tangible Book Value per Share
0.02
0.03
0.04
0.04
0.09
0.1
0.11
0.12
0.12
0.14
0.14
Basic Weighted Avg Shares
540
540
540
540
458
540
540
540
543
543
543
Sales/Revenue/Turnover
30
36
49
63
58
89
108
114
128
136
139
Operating Margin (%)
17.53
30.25
22.44
22.33
18.71
22.11
22.8
18.64
17.57
16.94
16.09
Depreciation Expense
4
4
5
6
6
7
8
10
15
16
17
Net Income, GAAP
3
7
4
8
6
12
15
13
13
14
13
Effective Tax Rate (%)
32.73
22.99
36.29
30.49
33.68
29.53
30.17
28.62
28.15
24.74
26.91
Profit Margin (%)
10.81
20.52
9.03
12.51
9.72
13.83
13.6
11.31
10.17
10.26
9.18
Working Capital
-4
-2
- -
-2
19
20
17
8
10
15
18
LT Debt
12
13
22
23
21
19
21
27
46
37
36
Total Equity
11
17
22
24
50
58
62
68
73
80
83
Return on Invested Capital (%)
- -
27.21
17.08
19.11
10.98
17.31
19.98
15.89
13.73
13.08
12.14
Return on Capital (%)
- -
26.39
11.44
15.75
9.08
15.63
16.27
13.24
11.6
11.33
9.91
Return on Common Equity (%)
- -
51.75
23.94
36.04
16
23.9
25.97
21.28
19.87
19.68
17.13

Capital Structure

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
12
12
15
LT Borrowings
15
15
14
LT Finance Leases
23
22
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
543
543
543
Market Capitalization
312
283
285

Working Capital

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
43
41
47
Cash, Cash Equivalents & STI
22
17
22
Accounts Receivable, Net
3
3
3
Inventories
7
9
9
Total Current Liabilities
29
26
29
Payables & Accruals
- -
- -
- -
ST Debt
12
12
15
Deferred Revenue
- -
- -
- -

Growth Rates

MYR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.83%
9.32%
Free Cash Flow
- -
-278.28%
-1,348.14%
Net Income, GAAP
- -
26.65%
7.24%
Sales/Revenue/Turnover
- -
19.71%
6.3%
Total Cash Common Dividend
- -
- -
-7.14%

Quarterly Revenue

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
28
32
33
34
128
2025
30
34
35
36
136
2026
31
37
- -
- -
- -

Quarterly Earnings Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.02
2025
0.01
0.01
0.01
0.01
0.03
2026
0.01
0.01
- -
- -
- -

Quarterly Dividends Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.01
2025
0.01
- -
- -
0.01
0.01
2026
0.01
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sing Yee Tan
Full Time Employees
288
Sector
Health services
Industry
Medical/Nursing services
Address
No.145, Jalan Radin Bagus Kuala Lumpur WP Malaysia 57000
IPO Date
Aug 18, 2020
Website
optimax2u.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Optimax Holdings Berhad (0222.KL) is a Malaysia-based investment holding company that provides comprehensive eye specialist services and related products through its network of ambulatory care centers, satellite clinics, and a specialist hospital primarily in Peninsular Malaysia. The company offers core ophthalmic services including refractive surgery such as ReLEx SMILE, Customised Femto-LASIK, Advanced Surface Ablation (ASA), Trans-Epithelial Surface Ablation (TESA), and Implantable Contact Lens (ICL); treatment of eye diseases and disorders encompassing no-blade cataract surgery (Femtosecond Laser-Assisted Cataract Surgery or FLACS), glaucoma management, diabetic eye disease, age-related macular degeneration, retinal detachment, cornea disease, pterygium, dry eyes, conjunctivitis, and lid disorders; consultation and dispensary services featuring doctor consultations, medication, and eye examinations for adults and children; oculoplastic surgery; and supplementary offerings such as sales of optical wear and consumables, Ortho-K for children, Botox, aesthetic and plastic surgery procedures, and administration fees. Founded in 1995 and headquartered in Kuala Lumpur, Optimax operates approximately 16 ambulatory care centers, eight satellite clinics, and one specialist hospital across central, southern, and eastern regions of Malaysia, serving over 500,000 patients with a focus on laser vision correction, cataract procedures, and pediatric eye care. Recent developments include the signing of a memorandum of understanding (MOU) with United Optometrist to channel patients from Singapore to its Malaysian facilities, progressive openings of new centers such as those at Kempas Hospital in Johor and Selgate Hospital in Rawang slated for 2026 with estimated capex of RM4-5 million each, ongoing updates to its MOU with Selgate Healthcare Sdn Bhd for potential collaboration, expansion plans into Indonesia, Vietnam, and building on its Cambodia venture, and expectations of record profits in 2025 driven by higher-value surgeries like LASIK and Presbyond amid seasonally strong refractive demand. The company, listed on Bursa Malaysia's Main Market since 2020, targets individual patients seeking advanced eye care solutions and continues to invest in regional growth and infrastructure to support earnings momentum into 2026-2027.